Clinical Trial Update: TP0502-Pharmaco-Scintigraphic-Study and Amendment [Phase 1]

View source ↗

Summary

Tillotts Pharma AG reports completion of a Phase 1 pharmaco-scintigraphic study and amendment for TP0502 in Ulcerative Colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• TP0502

Snippet

Sponsor: Tillotts Pharma AG | Conditions: Ulcerative Colitis | Phase 1 | Status: COMPLETED